Application for quotation of securities - TLX

14 Sep 2026
Read More

FDA Approves Telix Brain Cancer Imaging Drug Pixclara

14 Sep 2026
Read More

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

09 Sep 2026
MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley
Read More

Telix Completes Enrollment in Phase 3 BiPASS Study

02 Sep 2026
Read More

Telix Appoints David Gill as Chair

01 Sep 2026
Read More

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

19 Aug 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance 1: Double-digit revenue growth and gross margin
Read More

Telix HY26 Results Presentation

20 Aug 2026
Read More

Telix HY26 Results Announcement

20 Aug 2026
Read More

Telix HY26 Appendix 4D and Interim Report

20 Aug 2026
Read More

Telix to Host R&D Day in New York City on September 22, 2026

05 Aug 2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.
Read More
Displaying 1 - 10 of 135